Tarsus Pharmaceuticals Dividends and Buybacks
Dividend criteria checks 0/6
Tarsus Pharmaceuticals does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-0.3%
Buyback Yield
| Total Shareholder Yield | -0.3% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Narrative Update • Sep 08
TARS: Eye Disease Pipeline Expansion Will Drive Future Upside Potential
The analyst price target for Tarsus Pharmaceuticals has shifted from a fair value of $100.00 to $105.00 as analysts factor in updated assumptions for revenue growth, profit margins, and future P/E multiples, alongside a modest change in the discount rate. What’s in the News for Tarsus Pharmaceuticals Tarsus Pharmaceuticals completed the acquisition of Alkeus Pharmaceuticals, adding gildeuretinol (ALK-001), an oral investigational medicine in Phase 3 for Stargardt disease, to its pipeline.
Narrative Update • Aug 08
TARS: Alkeus Acquisition And Margin Outlook Will Support Future Upside
Analysts now see fair value for Tarsus Pharmaceuticals at $84, down from $88, reflecting updated assumptions that combine a higher discount rate, more moderate revenue growth expectations, a stronger projected profit margin, and a lower future P/E multiple. What’s in the News for Tarsus Pharmaceuticals Tarsus Pharmaceuticals announced an agreement to acquire Alkeus Pharmaceuticals in a deal valued at up to US$800 million in cash and stock, with potential additional payouts of US$350 million tied to future regulatory and sales milestones.Seeking Alpha • Jul 24
Tarsus Pharmaceuticals: Q2 2026 Rebound In Sales Possible, Catalysts Approaching
Summary TARS experienced a dip in net product sales in Q1'26, relative to Q4'25, the first decrease since Xdemvy launched. TARS reiterates 2026 Xdemvy net sales guidance of $670M–$700M, with Q2'26 prescription data indicating a potential recovery in Xdemvy and the ability to meet 2026 guidance. The iRenix Medical acquisition expands the pipeline with IRX-101, an ocular antiseptic, though revenues are several years out. Upcoming H1'27 trial readouts for Lyme prevention and ocular rosacea offer diversification and potential catalysts, backed by ample cash reserves. Read the full article on Seeking AlphaNarrative Update • Jun 24
TARS: Lyme Disease Prevention Trial Progress Will Drive Future Upside Potential
Analysts have modestly revised their price outlook on Tarsus Pharmaceuticals, citing updated expectations for revenue growth of about 36.9%, a profit margin near 34.5%, and a slightly lower assumed future P/E of roughly 11.7x, which together support the new price target relative to the prior fair value view of $100.00. What’s in the News for Tarsus Pharmaceuticals Tarsus Pharmaceuticals reported that the first participant has been dosed in the Phase 2 Calliope clinical trial evaluating TP-05, an investigational oral therapy intended to potentially prevent Lyme disease by killing infected ticks before transmission.
Narrative Update • Jun 09
TARS: Lyme Prevention Trial Progress Will Support Stronger Long Term Upside Potential
Analysts have lowered their price target on Tarsus Pharmaceuticals by about $1 to reflect updated assumptions for slightly lower revenue growth, a higher discount rate, and a different mix of profit margin and future P/E expectations. What's in the News Achieve Life Sciences appointed Tarsus CFO and Chief Strategy Officer Jeffrey Farrow to its Board of Directors, highlighting his experience with commercial launches and acquisitions.Narrative Update • May 26
TARS: Lyme Disease Prevention Program Will Support Future Upside Potential
Analysts have adjusted their price target on Tarsus Pharmaceuticals to $100, reflecting updated views on its revenue outlook, profit margins and future P/E assumptions. What's in the News Tarsus dosed the first participant in the Phase 2 Calliope trial of TP-05, an oral therapy designed to potentially prevent Lyme disease by killing infected ticks before transmission, with plans to enroll about 700 healthy adults across Lyme-endemic regions in the U.S. (company announcement) The Calliope trial is randomized, double blind and placebo controlled, and is designed to assess safety, tolerability and pharmacokinetics of TP-05 in adults at risk for Lyme disease, where there are currently no FDA approved pharmacological prophylactic options.Narrative Update • May 07
TARS: Lyme Disease Prevention Program Will Drive Future Upside Potential
Analysts have adjusted their price target on Tarsus Pharmaceuticals to $100 from $105, citing updated assumptions around the discount rate, revenue growth, profit margin, and future P/E that they see as better reflecting the stock's risk and earnings profile. What's in the News Tarsus started dosing participants in the Calliope Phase 2 trial of TP-05, an oral therapy being evaluated to potentially prevent Lyme disease by killing Lyme infected ticks before disease transmission, in about 700 healthy adults across Lyme endemic regions in the U.S. (Company announcement) Calliope is a randomized, double blind, placebo controlled study focused on the safety, tolerability, and pharmacokinetics of TP-05 in a population considered at risk for Lyme disease, for which there are currently no FDA approved pharmacological prophylactic options.Narrative Update • Apr 21
TARS: Lyme Prevention Pipeline Progress Will Support Stronger Long Term Outlook
Analysts have adjusted their price target on Tarsus Pharmaceuticals to reflect a shift in fair value from $87.50 to about $95.11, citing updated assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. What's in the News Tarsus began dosing participants in the Phase 2 Calliope trial of TP-05, an oral therapy being evaluated to potentially prevent Lyme disease by killing infected ticks before transmission, with a planned enrollment of about 700 healthy adults across U.S. regions where Lyme is common (Key Developments).Narrative Update • Apr 07
TARS: Lyme Prevention Program And China Milestone Will Support Future Upside
Analysts have raised their fair value estimate for Tarsus Pharmaceuticals from $100.00 to $105.00, reflecting updated assumptions regarding future revenue growth, profit margins, and a higher expected future P/E multiple. What's in the News Tarsus dosed the first participant in the Phase 2 Calliope trial of TP-05, an oral therapy designed to potentially prevent Lyme disease by killing infected ticks before transmission.Narrative Update • Mar 24
TARS: China Milestone And Margin Outlook Will Support Future Upside
Narrative Update: Tarsus Pharmaceuticals Analyst Price Target Shift Analysts have kept their $88.00 price target for Tarsus Pharmaceuticals steady while updating their models to reflect projected revenue growth of about 30% and a small improvement in expected profit margins, alongside a modestly lower future P/E assumption. Together, these adjustments indicate fine tuning of expectations rather than a change in the overall view.Narrative Update • Mar 09
TARS: Higher Fair Value And Future P/E Will Support Upside
Analysts have lifted their price target for Tarsus Pharmaceuticals from about $60.06 to $88.00, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E as the key drivers behind the change. Valuation Changes Fair value was raised from about $60.06 to $88.00, suggesting a higher assessed equity value for Tarsus Pharmaceuticals.Narrative Update • Feb 23
TARS: Higher Earnings Power And Lower Future P/E Will Support Upside
Analysts have adjusted their price target on Tarsus Pharmaceuticals to reflect updated assumptions for revenue growth of about 47.48%, profit margin of about 45.30% and a future P/E of about 9.89x. Together, these factors point to a meaningfully different view on the stock's earnings power under current models.Narrative Update • Feb 09
TARS: Higher Future P/E Assumptions Will Support A More Optimistic Outlook
Analysts have increased their price target for Tarsus Pharmaceuticals from US$92.00 to US$100.00, citing updated assumptions around long term revenue growth, profit margins, and a higher future P/E multiple in their valuation work. Valuation Changes Fair Value: Updated from US$92.00 to US$100.00, reflecting a higher assessed equity value per share.Analysis Article • Feb 06
Shareholders Should Be Pleased With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Price
Tarsus Pharmaceuticals, Inc.'s ( NASDAQ:TARS ) price-to-sales (or "P/S") ratio of 7.2x might make it look like a strong...Narrative Update • Jan 26
TARS: Revenue Guidance And Rich Multiple Will Likely Overstate Future Upside
Analysts now see a slightly lower fair value for Tarsus Pharmaceuticals at about US$60.06 per share, down from roughly US$60.99. This reflects updated assumptions around discount rate, revenue growth, profit margin and future P/E.Analysis Article • Jan 15
Does Tarsus Pharmaceuticals (NASDAQ:TARS) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Narrative Update • Jan 10
TARS: Elevated Profit Assumptions Will Likely Overstate Future Earnings Power
Analysts have lifted their price target on Tarsus Pharmaceuticals from about $49.58 to roughly $60.99, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels. What's in the News Tarsus Pharmaceuticals issued full year 2025 revenue guidance in the range of $440 million to $445 million.Narrative Update • Dec 26
TARS: Future Revenue Guidance And Margins Will Support Balanced Long-Term Outlook
Analysts have modestly reaffirmed their outlook on Tarsus Pharmaceuticals, maintaining the fair value estimate at approximately 87.50 dollars. They continue to anticipate robust, high margin revenue growth supported by strong, long term fundamentals.Narrative Update • Dec 12
TARS: Future Revenue Guidance And Margins Will Support Balanced Long-Term Outlook
Analysts have modestly raised their price target on Tarsus Pharmaceuticals to approximately $88 per share from about $86, citing slightly improved fair value estimates driven by updated assumptions for long term revenue growth, profit margins, and valuation multiples. What's in the News Issued new full-year 2025 revenue guidance, projecting annual revenue of $440 million to $445 million, based on company guidance about anticipated commercial performance.Narrative Update • Nov 28
TARS: Future Revenue Momentum And Margin Shifts Will Support Stable Long-Term Outlook
Analysts have raised their price target for Tarsus Pharmaceuticals, increasing the estimated fair value from $84.25 to $86.11. This change is based on improved expectations for revenue growth, even as other key financial assumptions were adjusted.Narrative Update • Nov 14
TARS: Future Profit Margin Expansion Will Drive Stronger Financial Performance
Analysts have raised their price target for Tarsus Pharmaceuticals from $80.38 to $84.25, citing improved profit margin forecasts and a more favorable valuation outlook. What's in the News Tarsus Pharmaceuticals has issued new corporate guidance for the fourth quarter of 2025, predicting annual revenue in the range of $440 million to $445 million (Key Developments).Narrative Update • Oct 31
TARS: Rising Margins And Patient Demand Will Drive Future Outperformance
Analysts have raised their price target on Tarsus Pharmaceuticals from $78.38 to $80.38, citing expectations for stronger revenue growth and improved profit margins. Valuation Changes Fair Value has increased from $78.38 to $80.38.Analysis Article • Oct 18
Market Participants Recognise Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Revenues Pushing Shares 41% Higher
Tarsus Pharmaceuticals, Inc. ( NASDAQ:TARS ) shares have continued their recent momentum with a 41% gain in the last...Narrative Update • Oct 16
Broad Patient Adoption And Global Expansion Will Open Long-Term Opportunities
Analysts have increased their price target for Tarsus Pharmaceuticals, raising the estimated fair value from $76.00 to $78.38. This adjustment is based on updated financial projections and ongoing confidence in the company's growth prospects.Narrative Update • Aug 28
Broad Patient Adoption And Global Expansion Will Open Long-Term Opportunities
With both Tarsus Pharmaceuticals’ future P/E ratio (19.91x) and net profit margin (27.99%) remaining stable, there is no shift in analyst sentiment or valuation, and the consensus analyst price target is unchanged at $76.00. What's in the News Dropped from Russell Microcap Growth Benchmark Index Dropped from Russell 3000E Growth Benchmark Dropped from Russell 3000E Index Dropped from Russell Microcap Index Dropped from Russell 3000E Growth Index Valuation Changes Summary of Valuation Changes for Tarsus Pharmaceuticals The Consensus Analyst Price Target remained effectively unchanged, at $76.00.Analysis Article • Jul 30
Why Investors Shouldn't Be Surprised By Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) P/S
With a price-to-sales (or "P/S") ratio of 7.2x Tarsus Pharmaceuticals, Inc. ( NASDAQ:TARS ) may be sending bearish...New Narrative • May 27
Expanding Ocular And Parasitic Markets Will Drive Future Value
Strong growth driven by expanding XDEMVY adoption, a broader addressable market, favorable demographics, and new indications and geographies diversifying revenue streams.Analysis Article • Apr 02
With Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) It Looks Like You'll Get What You Pay For
Tarsus Pharmaceuticals, Inc.'s ( NASDAQ:TARS ) price-to-sales (or "P/S") ratio of 10.3x might make it look like a...Seeking Alpha • Mar 11
Tarsus Pharma: Strong Execution In Xdemvy Commercialization
Summary Tarsus Pharmaceuticals' Xdemvy, the first approved treatment for Demodex blepharitis, generated $180M in 2024 sales, with significant growth potential in a large addressable market. Analysts project Tarsus' revenue to reach $352M in 2025, driven by expanding sales, Medicare/Medicaid reimbursement, and increasing consumer awareness. Tarsus' pipeline includes promising candidates TP-04 for Ocular Rosacea and TP-05 for Lyme disease, enhancing long-term growth prospects. With a 12-month price target of $56.25/share, TARS stock is a BUY for aggressive growth investors, poised for profitability by 2026. Read the full article on Seeking AlphaAnalysis Article • Feb 07
Is Tarsus Pharmaceuticals (NASDAQ:TARS) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Jan 23
Tarsus: Promising Investment, But Timing Is The Key
Summary Tarsus Pharmaceuticals' lead asset, lotilaner (XDEMVY), has shown strong market performance, achieving a 75% stock increase since August despite initial doubts. Lotilaner, approved for Demodex blepharitis, is the only approved treatment, demonstrating high efficacy and strong launch metrics, with $113 million in annual revenue. Despite a Q3 sales dip attributed to seasonality, Tarsus maintains a robust pipeline, including promising phase 2 trials for ocular rosacea and Lyme disease. With a solid financial position and a cash runway of over 10-12 quarters, Tarsus remains a cautious investment due to the lack of near-term catalysts. Read the full article on Seeking AlphaSeeking Alpha • Dec 10
Tarsus Pharmaceuticals: Early Rollout Exceeding Expectations
Summary Tarsus Pharmaceuticals, Inc.'s stock has rebounded to near all-time highs in 2024 after a significant sell-off post-IPO in 2020. The early rollout of XDEMVY has easily exceeded expectations, with the company handily beating consensus estimates with its Q2 and Q3 results. Shareholders have been rewarded with an approximate 55% rally in the stock over the past six months. Can the rally continue? An updated analysis around Tarsus Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaAnalysis Article • Nov 16
US$65.33 - That's What Analysts Think Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Is Worth After These Results
Tarsus Pharmaceuticals, Inc. ( NASDAQ:TARS ) just released its quarterly report and things are looking bullish. The...Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if TARS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TARS's dividend payments have been increasing.
Dividend Yield vs Market
| Tarsus Pharmaceuticals Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (TARS) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Pharmaceuticals) | 1.8% |
| Analyst forecast (TARS) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate TARS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TARS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate TARS's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as TARS has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/21 08:27 |
| End of Day Share Price | 2026/09/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tarsus Pharmaceuticals, Inc. is covered by 19 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jenna Davidner | Barclays |
| Jason Matthew Gerberry | BofA Global Research |
| Andrea Newkirk | Goldman Sachs |